Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment